Approval · Notice of Compliance 8315 · 2006
COVERSYL: Notice of Compliance 8315
Issued October 11, 2006
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 8315
- Date
- October 11, 2006
- Company
- Servier Canada Inc.Laval, Quebec, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- Supplement to a New Drug Submission (SNDS), supplement
- Submission class
- Other
- Reason
- New indication: coversyl has been demonstrated to reduce the risk of cardiovascular death, non-fatal myocardial infarction, and cardiac arrest in mild or moderately hypertensive patients with stable coronary artery disease, or in patients previous (>3 months ago) myocardial infarction and stable coronary artery disease, when administered as an add-on to conventional treatment, such as platelet inhibitors, beta blockers, lipid-lowering agents, nitrates, calcium channel blockers or diuretics
- Therapeutic class
- Angiotensin converting enzyme inhibitor
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| COVERSYL | Not yet assigned | — |
Medicinal ingredients
- PERINDOPRIL ERBUMINE 2 MG per TAB
- PERINDOPRIL ERBUMINE 4 MG per TAB
- PERINDOPRIL ERBUMINE 8 MG per TAB